Virios Therapeutics cuts cash compensation 10%; grants stock options to officers and directors

Dogwood Therapeutics, Inc.

Board approved 10% salary reduction for all employees including executive officers, effective March 1, 2024.
Non-employee director cash compensation also reduced by 10%.
Stock options granted to executive officers and directors: CEO Greg Duncan receives 138,835 options; total 410,570 options across 10 recipients.
Options have exercise price of $0.357/share and vest on February 26, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.